Akebia Q2 2026: Vafseo revenue $21.3M (+34% QoQ); net loss $8.9M

Akebia Therapeutics, Inc.

Vafseo net product revenue $21.3M in Q2 2026, up 34% from Q1; over 10,500 patients on therapy.
Total revenue $49.1M, down 20% YoY due to Auryxia generic competition ($25.5M vs $47.2M).
Net loss of $8.9M vs net income of $0.2M in Q2 2025; includes $1.9M restructuring charge.
Cash $155.5M as of June 30; company expects to fund operations for at least two years.
Initiated Phase 2 basket trial of ebribafusp for rare kidney diseases; initial data expected 2027.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.